CLINICAL TRIAL

Treatment for Solid Organ Transplant

Waitlist Available · 18+ · All Sexes · Los Angeles, CA

Trial to Compare the SherpaPak™ Device vs Cold Storage

See full description

About the trial for Solid Organ Transplant

Treatment Groups

This trial involves a single treatment. Treatment is the primary treatment being studied. Participants will all receive the same treatment. There is no placebo group. The treatments being tested are not being studied for commercial purposes.

Main TreatmentA portion of participants receive this new treatment to see if it outperforms the control.
Control TreatmentAnother portion of participants receive the standard treatment to act as a baseline.

Eligibility

This trial is for patients born any sex aged 18 and older. There are 4 eligibility criteria to participate in this trial as listed below.

Inclusion & Exclusion Checklist
Mark “yes” if the following statements are true for you:
for a transplant at our hospital, UCLA People who need a transplant must find a donor who is not local. show original
Any person aged 18 or over who is of either sex is eligible for a heart transplant. show original
View All
Odds of Eligibility
Unknown<50%
Be sure to apply to 2-3 other trials, as you have a low likelihood of qualifying for this one.Apply To This Trial
Similar Trials

Approximate Timelines

Please note that timelines for treatment and screening will vary by patient
Screening: ~3 weeks
Treatment: varies
Reporting: 30 days post-transplant
This trial has approximate timelines as follows: 3 weeks for initial screening, variable treatment timelines, and reporting: 30 days post-transplant.
View detailed reporting requirements
Trial Expert
Connect with the researchersHop on a 15 minute call & ask questions about:
- What options you have available- The pros & cons of this trial
- Whether you're likely to qualify- What the enrollment process looks like

Measurement Requirements

This trial is evaluating whether Treatment will improve 1 primary outcome and 3 secondary outcomes in patients with Solid Organ Transplant. Measurement will happen over the course of 24 hours post-transplant.

Absence of moderate to severe primary graft dysfunction (left or right ventricle)
24 HOURS POST-TRANSPLANT
Percentage of subjects without moderate to severe primary graft dysfunction (left or right ventricle)
Quantify Hemodynamic parameters
24 HOURS POST-TRANSPLANT
Percentage of Cardiac index, cardiac output, blood pressure, mean arterial pressure, pulmonary artery pressure, left atrial pressure, right atrial pressure, right ventricular pressure, stroke volume and ejection fraction
Incidence of antibody mediated rejection
30 DAYS POST-TRANSPLANT
Percentage of subjects with no antibody mediated rejection in the first 30 days after transplant.
Incidence of acute cellular rejection
30 DAYS POST-TRANSPLANT
Percentage of subjects without acute cellular rejection in the first 30 days after transplant

Who is running the study

Principal Investigator
F. E.
Prof. Fardad Esmailian, Professor of Surgery
Cedars-Sinai Medical Center

Patient Q & A Section

Ask a question about the study

Other questions from users

Please Note: These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Are there any geographic restrictions to consider when applying for this trial?

Patients from any state can participate in this trial, so long as they are able to attend all treatment sessions.

Will my insurance cover participating in this trial?

In order to understand how insurance coverage works for this trial, you will need to contact the study coordinator.

See if you qualify for this trial
Get access to this novel treatment for Solid Organ Transplant by sharing your contact details with the study coordinator.